FRANCISCO DE PAULA
TELLEZ PEREZ
Profesor asociado de Ciencias de la Salud
Hospital Universitario Puerta del Mar
Cádiz, EspañaPublications in collaboration with researchers from Hospital Universitario Puerta del Mar (13)
2021
-
Acute hepatitis C virus infection and direct-acting antiviral drugs: Perfect combination to eliminate the epidemic?
International Journal of STD and AIDS, Vol. 32, Núm. 13, pp. 1257-1260
-
Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy
Journal of Hepatology, Vol. 74, Núm. 4, pp. 801-810
2017
-
Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 36, Núm. 3, pp. 487-494
2015
-
Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 34, Núm. 9, pp. 1879-1884
2014
-
Clinical and virological efficacy of etravirine plus two active nucleos(t)ide analogs in an heterogeneous HIV-infected population
PLoS ONE, Vol. 9, Núm. 5
-
Predictors of early mortality in very elderly patients with bacteremia: A prospective multicenter cohort
International Journal of Infectious Diseases, Vol. 26, pp. 83-87
2013
-
Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis
Clinical Infectious Diseases, Vol. 56, Núm. 11, pp. 1646-1653
-
Reappraisal of the outcome of healthcare-associated and community-acquired bacteramia: A prospective cohort study
BMC Infectious Diseases, Vol. 13, Núm. 1
-
Short communication: Atazanavir-based therapy is associated with higher hepatitis C viral load in HIV type 1-infected subjects with untreated hepatitis C
AIDS Research and Human Retroviruses, Vol. 29, Núm. 2, pp. 223-225
2012
-
Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients
AIDS, Vol. 26, Núm. 13, pp. 1721-1724
-
Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: A propensity score-based analysis
Antimicrobial Agents and Chemotherapy, Vol. 56, Núm. 1, pp. 472-478
-
Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis
Clinical Infectious Diseases, Vol. 55, Núm. 12, pp. 1719-1726
2010
-
Epidemiology and clinical features of community-acquired, healthcare-associated and nosocomial bloodstream infections in tertiary-care and community hospitals
Clinical Microbiology and Infection, Vol. 16, Núm. 9, pp. 1408-1413